Cite
HARVARD Citation
Bringhen, S. et al. (2019). Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. Journal of internal medicine. pp. 63-74. [Online].